Amsbio Expands Catalog With 10,000 Validated Antibodies

Amsbio has expanded its diverse range of recombinant and monoclonal antibodies to include over 10,000 new validated monospecific products in 15,000 formulations to support research in cancer, immunology, neuroscience, and signal transduction.

Every antibody in the new catalogue has been subject to rigorous validation technologies to confirm that they selectively recognize their intended targets across applications such as immunohistochemistry, western blot, flow cytometry and immunofluorescence. These recombinant and monoclonal antibodies also provide high sensitivity and minimal background signal, reducing the risk of false positives or non-specific binding.

Recombinant antibodies are a premium class of antibodies engineered through genetic manipulation techniques. They provide precision targeting, consistency and reproducibility, customization, scalability, and reduced immunogenicity, making them an invaluable tool for research, diagnostics, and therapeutics.  Monoclonal antibodies are identical antibodies derived from a single clone of B cells, meaning they all recognize the same specific epitope on an antigen. They are used to target specific antigens in diagnosis, treatment, and research into various diseases including cancer and autoimmune disorders

Benefiting from a completely controlled production process, the batch-to-batch reproducibility of these monospecific antibodies is exceptional, which is vital for longer term experiments. All these antibodies are developed and tested across hundreds of tumour types and normal tissues to ensure accurate epitope mapping and binding affinity.

This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.